Spero Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Spero Therapeutics, Inc. (SPRO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.74 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Spero Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 7.74M shares, a 6.62% decline year-over-year.
- Spero Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 7.92M shares, a 27.38% decline year-over-year.
- Spero Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 7.85M shares, a 24.13% decline year-over-year.
- Spero Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 8.29M shares, a 21.40% decline year-over-year.
- Spero Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 2.73M shares, a 69.22% decline from fiscal 2024.
- Spero Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 8.85M shares, a 27.43% increase from fiscal 2023.
- Spero Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.95M shares, a 31.60% increase from fiscal 2022.
- Spero Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.28M shares, a 55.15% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 7.74M shares 10-Q · filed 2026-08-12 | 7.74M shares 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 7.92M shares 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | 2.73M shares 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | 7.85M shares 10-Q · filed 2025-11-13 | 7.85M shares 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 8.29M shares 10-Q · filed 2026-08-12 | 8.29M shares 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | 10.91M shares 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | 8.85M shares 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | 10.35M shares 10-Q · filed 2025-11-13 | 10.35M shares 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | 10.55M shares 10-Q · filed 2025-08-12 | 10.55M shares 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 10.42M shares 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | 6.95M shares 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | 7.75M shares 10-Q · filed 2024-11-14 | 7.75M shares 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | 8.49M shares 10-Q · filed 2024-08-05 | 8.49M shares 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | 8.37M shares 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 5.28M shares 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | 5.16M shares 10-Q · filed 2023-11-13 | 5.16M shares 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | 9.89M shares 10-Q · filed 2023-08-10 | 9.89M shares 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 13.31M shares 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 11.77M shares 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | 11.56M shares 10-Q · filed 2022-11-14 | 11.56M shares 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 10.95M shares 10-Q · filed 2022-08-10 | 10.95M shares 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | 10.95M shares 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | 10.21M shares 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | 11.93M shares 10-Q · filed 2021-11-10 | 11.93M shares 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 8.71M shares 10-Q · filed 2021-08-05 | 8.71M shares 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 8.70M shares 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | 5.73M shares 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | 5.86M shares 10-Q · filed 2020-11-05 | 5.86M shares 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 5.87M shares 10-Q · filed 2020-08-06 | 5.87M shares 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 6.35M shares 10-Q · filed 2020-05-08 | 6.35M shares 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | 5.52M shares 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | 4.41M shares 10-Q · filed 2019-11-04 | 4.41M shares 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | 2.24M shares 10-Q · filed 2019-08-08 | 2.24M shares 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | 2.13M shares 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | 2.01M shares 10-K · filed 2019-03-14 | ||||
| 2017-09-30 | 9.60M shares 10-Q · filed 2018-11-08 | 9.60M shares 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | 8.05M shares 10-Q · filed 2018-08-09 | 8.05M shares 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | 422.40K shares 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | 2.64M shares 10-K · filed 2019-03-14 | ||||
| 2016-09-30 | 2.64M shares 10-Q · filed 2017-12-14 | ||||
| 2015-12-31 | 1.43M shares 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |